Cytokines in Cancer Immunotherapy (2nd Edition)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 2973

Special Issue Editors


E-Mail Website
Guest Editor
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA
Interests: interferon; leukemia; immunotherapy; cytokines; signaling
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. University Health Network, Toronto, ON, Canada
2. International Collaborations & Initiatives, Department of Immunology, University of Toronto, Toronto, ON, Canada
3. Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Interests: interferons; chemokines; infectious diseases; autoimmune diseases; antivirals
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

This collection is the second edition of the Special Issue Cytokines in Cancer Immunotherapy.

This Special Issue will address the roles of key cytokines in the immune response to cancer and the generation of antitumor responses. The Issue will address the role of interferons in the immune response and their importance to cancer immunotherapy. It will discuss the mechanisms by which cytokines control the avidity and function of anti-tumor T cells and will provide an overview of the mechanisms of promotion of tumor development and the immune escape by interleukin 33 signaling. In addition, the role of the heterodimeric intereleukin-15 in tumor immunotherapy will be addressed. Finally, the roles of cytokines in the progression of brain metastases will be discussed. Overall, the Issue will provide a comprehensive review of the roles of different cytokines in the immunotherapy of tumors.

Prof. Dr. Leonidas C Platanias
Prof. Dr. Eleanor N. Fish
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotherapy
  • interferons
  • cytokines
  • interleukin
  • T cells
  • immune escape

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

22 pages, 2319 KiB  
Review
Signaling by Type I Interferons in Immune Cells: Disease Consequences
by Markella Zannikou, Eleanor N. Fish and Leonidas C. Platanias
Cancers 2024, 16(8), 1600; https://doi.org/10.3390/cancers16081600 - 22 Apr 2024
Cited by 3 | Viewed by 2278
Abstract
This review addresses interferon (IFN) signaling in immune cells and the tumor microenvironment (TME) and examines how this affects cancer progression. The data reveal that IFNs exert dual roles in cancers, dependent on the TME, exhibiting both anti-tumor activity and promoting cancer progression. [...] Read more.
This review addresses interferon (IFN) signaling in immune cells and the tumor microenvironment (TME) and examines how this affects cancer progression. The data reveal that IFNs exert dual roles in cancers, dependent on the TME, exhibiting both anti-tumor activity and promoting cancer progression. We discuss the abnormal IFN signaling induced by cancerous cells that alters immune responses to permit their survival and proliferation. Full article
(This article belongs to the Special Issue Cytokines in Cancer Immunotherapy (2nd Edition))
Show Figures

Figure 1

Back to TopTop